The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.

Start Date09 Jan 2023

Sponsor / Collaborator

Oregon Health & Science University

100 Clinical Results associated with Ulipristal Acetate

100 Translational Medicine associated with Ulipristal Acetate

100 Patents (Medical) associated with Ulipristal Acetate

987

Literatures (Medical) associated with Ulipristal Acetate

01 Mar 2025·Theriogenology

Foals born alive from mares with ultrasonographically assessed placental abnormalities: Neonatal health and development up to weaning compared to foals from healthy mares

Article

Author: Debes, Leonie ; Blanco, Miguel ; Venner, Monica ; Sieme, Harald ; Koether, Karoline ; Sielhorst, Jutta ; Vervuert, Ingrid

Little is known about the health status of foals born alive from mares treated for placental disease. The aims of the present study were (1) to compare the neonatal health status and health development during the rearing period of foals born from mares treated for ultrasonographically assessed placental abnormalities (UPA) to age-matched healthy foals from the same warmblood stud and (2) analyze the influence of mare's placental health on colostrum quality. Foals (n = 127) born from mares with UPA (UPA group; P) in 2017-2019 were compared to 127 foals born from healthy mares (control group; C). Sixty-six UPA mares showed subclinical placental abnormalities (PSc1) and 61 mares showed clinical placental abnormalities (PSc2). The colostrum quality assessed by refractometry showed that healthy mares had 42 excellent (>30 %), 73 good (20-30 %) and 6 poor (<20 %) colostrum, whereas UPA mares showed 29 excellent, 66 good and 26 poor colostrum quality (P < 0.001). The administration of high-quality colostrum was more frequent in the UPA group (17.5 %) than in C (7.9 %; P = 0.024). The mean (±SD) gestation length of UPA mares was shorter (330 ± 11 days) and foal birth weight lower (54.2 ± 7.3 kg) compared to the healthy pregnancies (335 ± 11 days; P = 0.002 and 57.0 ± 6.6 kg; P < 0.001). The number of foals with a reduced immunoglobin G concentration 14 h postpartum was significantly higher in PSc2 (P = 0.007). Foals born from UPA mares received foreign plasma (P 25.4 % vs C 4.2 %; P = 0.028) more frequently. Premature placental separation, the occurrence of the retention of fetal membranes, placental weight, foal vitality and the white blood cell count did not differ between groups. Regarding the health status of the foal in the neonatal period (1-14 days postpartum), 10 foals (8.1 %) born from UPA pregnancies showed maladjustment syndrome, whereas none of the foals in the control group showed this condition (P < 0.001). Foals from UPA mares developed diarrhea more often (P 31.4 % vs C 19.9 %; P = 0.042), whereas omphalitis, pneumonia, sepsis, meconium obstipation and contracted tendons did not differ between the groups. Multimorbidity and treatment were more frequent in foals born from UPA pregnancies (P 12.8 % vs C 4.7 %; P = 0.004 and 59.6 % vs 40.4 %; P = 0.007). In conclusion, foals born alive from UPA mares face decreased immunity and an increased risk of disease during the first 14 days postpartum. The study underlines that colostrum supplementation from a healthy mare seems essential in UPA pregnancies.

11 Feb 2025·Expert Opinion on Pharmacotherapy

Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update

Review

Author: Tureli, Dilruba ; Giani, Milo ; Speciale, Anna Rosa ; Vannuccini, Silvia ; Fambrini, Massimiliano ; Ozpinar, Kubra ; Petraglia, Felice

INTRODUCTIONDysmenorrhea is a painful symptom associated with uterine contractions and menstrual bleeding and is treated by administering analgesic drugs. Since progesterone receptors (PRs) have a major role in regulating uterine tissues (myometrium and endometrium) physiology, oral contraceptives are used off-label for treating primary or secondary dysmenorrhea. The development of selective progesterone receptor modulators (SPRMs), a class of synthetic steroids with agonistic, antagonistic, or mixed effects in targeting PRs in different tissues, stimulated their possible clinical use for treating secondary dysmenorrhea related to uterine diseases (endometriosis, adenomyosis, uterine fibroids).AREAS COVEREDThe present review examines the development of the clinical trials and observational studies done with the different SPRMs for the treatment of dysmenorrhea in patients with uterine diseases.EXPERT OPINIONMifepristone, telapristone acetate and vilaprisan have antagonistic activity on PRs, whereas ulipristal acetate and asoprisnil have both potent antagonist and partial agonist effects.Since no studies have been done on primary dysmenorrhea, the different SPRMs have been evaluated in the treatment of endometriosis, adenomyosis and uterine fibroid-related dysmenorrhea.

06 Feb 2025·Inflammatory Bowel Diseases

Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn’s Disease

Article

Author: Xuan, Si ; Shukla, Nidhi ; Loftus, Edward V ; Joshi, Namita ; Panés, Julian ; Louis, Edouard ; Lacerda, Ana P ; Kligys, Kristina ; Lee, Wan-Ju ; Bossuyt, Peter

AbstractBackgroundWe evaluated the association of achieving endoscopic outcomes at week 12 of induction with improvements in clinical outcomes and quality of life (QoL) at week 52 of maintenance in patients with moderately to severely active Crohn’s disease (CD) treated with upadacitinib (UPA).MethodsThis post hoc analysis evaluated data from 2 phase 3 induction trials (NCT03345836 and NCT03345849) and 1 maintenance (NCT03345823) trial. Clinical responders to 12-week induction therapy with UPA who also received 52-week maintenance treatment with UPA were included. Endoscopic response, remission, healing, and ulcer-free endoscopy were assessed at week 12. Meaningful improvements in clinical and QoL outcomes were evaluated at week 52.ResultsA significantly greater proportion of patients who achieved an endoscopic response at the end of induction, compared with patients who did not, attained Crohn’s Disease Activity Index (CDAI) remission (52.0% vs 34.6%; P ≤ .01), corticosteroid-free CDAI remission (50.0% vs 30.9%), Inflammatory Bowel Disease Questionnaire remission (52.6% vs 30.3%), and meaningful improvements in Functional Assessment of Chronic Illness Therapy—Fatigue response (46.7% vs 25.9%), overall work impairment (47.1% vs 26.5%), and daily activity impairment (53.3% vs 34.1%) (all P < .05) at week 52. Similar findings were observed for patients who achieved endoscopic remission, endoscopic healing, and ulcer-free endoscopy at the end of induction vs those who did not.ConclusionsEarly improvement in endoscopic outcomes after UPA induction treatment was associated with long-term meaningful improvements in clinical outcomes and QoL in patients with CD.Clinical Registration numberU-EXCEED induction trial (NCT03345836), U-EXCEL induction trial (NCT03345849), and U-ENDURE maintenance trial (NCT03345823).

News (Medical) associated with Ulipristal Acetate

24 Jan 2025

·www.drugs.com

Abortion Pill Alternative Found in Morning-After Pill

FRIDAY, Jan. 24, 2025 -- When one abortion pill faces lawsuits, another may be waiting in the wings, a new study suggests. The study, published Jan. 23 in the journal NEJM Evidence , has found a potential alternative to the abortion pill mifepristone , offering yet another option at a time when access to reproductive health care faces increasing legal and political challenges. Researchers tested ulipristal acetate, the active ingredient in the emergency contraceptive pill Ella , as a substitute for mifepristone in the medication abortion regimen. The study found that when ulipristal acetate was used at double the typical dose of Ella followed by misoprostol, the regimen was 97% effective in terminating pregnancies up to nine weeks. No serious complications were reported among the 133 women who participated. All but four completed the termination of their pregnancies without further intervention, researchers reported. The findings dovetail with ongoing lawsuits targeting mifepristone, the only drug specifically approved for abortion in the United States. Typically, it works by blocking progesterone, a hormone necessary for pregnancy, and is followed by misoprostol, which causes contractions to end the pregnancy. Lead author Dr. Beverly Winikoff , president of the reproductive health research organization Gynuity Health Projects, told The New York Times that the U.S. Supreme Court’s 2022 decision to overturn Roe v. Wade increased her interest in exploring alternatives to mifepristone. “I was thinking, there’s maybe something else we can do,” Winikoff said. “Another option. And this one is already on the market.” It's important to note, however, that reproductive health experts warn that the study could fuel political controversy, because Ella is also marketed as a prescription morning-after pill to prevent pregnancy following unprotected sex. Abortion foes have long argued that morning-after pills like Ella can act as abortifacients, substances that cause abortion. These claims have been strongly debunked. Evidence shows that Ella, when taken at its standard 30-milligram dose, works by delaying ovulation, preventing fertilization. This study, which used a 60-milligram dose of ulipristal acetate combined with misoprostol, does not debunk the science of emergency contraception . But it may blur public perceptions of the line between contraception and abortion. “It’s going to put wind in the sails of abortion opponents who have been saying things like contraceptives can be abortifacients,” Mary Ziegler , a law professor and abortion expert at the University of California, Davis, told The Times. “This study being released will be difficult, I think, for abortion rights supporters to manage.” Kristi Hamrick , a spokeswoman for Students for Life of America, said her organization would “absolutely” consider litigation over Ella. “The pro-life movement should be vindicated,” Hamrick told The Times . “We’ve been arguing for years that Ella acts as an abortifacient.” While the results are promising, experts say more research is needed before ulipristal acetate could replace mifepristone. “We can’t change clinical practice based on this study,” Kelly Cleland , executive director of the American Society for Emergency Contraception, told The Times. Dr. Daniel Grossman , a reproductive health researcher at the University of California, San Francisco, called the findings “promising.” But he warned that “if because of this new evidence that at higher doses, ulipristal acetate could cause an abortion, that were to lead to ulipristal acetate being taken off the market for emergency contraception, that would be really, really bad.” The study was conducted in Mexico City and was co-led by researchers there. “The more uses we have for these medications, the harder it will be for people to take them away,” Dr. Paul Blumenthal , an emeritus professor of obstetrics and gynecology at Stanford University who was in an advisory group for the study, concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalClinical Study

27 Aug 2024

·www.prnewswire.com

ScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine

ST. PAUL, Minn., Aug. 27, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant. Dr. Feldman's $300,000 G-Rex Grant will enable expeditious development of Stanford Medicine's LCGM's G-Rex platform for CAR-T cell therapy manufacturing, which will be offered to internal investigators and external developers who are seeking its development and manufacturing services. "Stanford's LCGM anticipates a need to support a greater number of clinical trials and the G-Rex Grant will be used to help meet that need," said Dr. Feldman. "We are honored to award the inaugural G-Rex Grant to Dr. Feldman and his team at Stanford Medicine LCGM. Stanford University is a world-class institution with faculty who have a reputation for innovative and ground-breaking achievements. Their work aligns with Wilson Wolf's mission of bringing hope to cancer patients, one G-Rex at a time" said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of the G-Rex Grant, Stanford Medicine LCGM will deploy their G-Rex-centric manufacturing process in an upcoming Phase 1 trial for GPC2+ pediatric neuroblastoma and medulloblastoma. Previously, the FDA had recommended sponsors develop and implement potency assays earlier in the clinical trial process. With that objective, Stanford Medicine LCGM plans to implement Bio-Techne's leading automated multiplexing immunoassay platform, Ella™, as a potency assay for final drug product release. Furthermore, Stanford Medicine LCGM will collaborate with CellReady, the world's first and only G-Rex based contract development and manufacturing organization (CDMO), to leverage their proven capacity to quickly create G-Rex master batch records that establish manufacturing simplicity, efficiency, and repeatability. Additionally, Stanford Medicine LCGM plans to further develop a novel technology (developed by Wilson Wolf) that enables closed-system T cell purification to be done directly in a G-Rex device, without the need for expensive ancillary equipment. ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About ScaleReady ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 4 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact [email protected]. About Wilson Wolf Manufacturing Wilson Wolf () is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex® centric contract development and manufacturing organization (CDMO) specializing in G-Rex® based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. SOURCE Bio-Techne Corporation

Cell TherapyImmunotherapyGene Therapy

08 Aug 2024

·www.biospace.com

Gameto Expands Executive Team with the Addition of Teri Loxam as Chief Financial Officer

NEW YORK, April 28, 2023 /PRNewswire/ -- Gameto, a female-led biotech company developing therapies to improve the female reproductive journey, today announced the expansion of its executive team with the appointment of Teri Loxam as its first Chief Financial Officer. In this new role, Teri will oversee Gameto's financial function, as well as play a key role in overall company strategy. "Teri is a proven CFO and an impressive female leader, whose decades of experience will immediately add value to our company," said Dina Radenkovic, co-founder and CEO of Gameto. "Her depth of knowledge in capital markets and financing in the biotechnology and pharmaceutical industries comes at an exciting time for the company as we work on clinical development and go-to-market strategy for our lead program, Fertilo, to make the IVF process shorter, safer and more effective for women. Teri's personal passion for women's health is extremely important to us as we continue to grow." Teri joins Gameto with over 20 years of diverse experience in strategy, investor relations and finance across the pharmaceutical, biotech, and TMT industries. Prior to joining Gameto, Teri was Chief Operating Officer & Chief Financial Officer at Kira Pharmaceuticals, a clinical-stage biotech company developing transformative therapies for people with complement-mediated diseases. There, she built financial and operational functions across the U.S. and China locations to get the company public-ready. Prior to Kira, Teri served as CFO of SQZ Biotechnologies, a novel cell therapy company developing treatments for cancer, infectious disease and other serious conditions, where she raised over $200M, including taking the company public in October 2020. Prior to joining SQZ, Teri held various positions at Merck, IMAX Corporation, and Bristol-Myers Squibb. Teri is also a member of the board of directors and audit chair of Vaxcyte, Inc. and Cardiol Therapeutics, Inc. She has a B.S. in Biology from the University of Victoria, B.C. Canada and an MBA from the University of California, Irvine. "Gameto's highly innovative platform and dedication to improve and support women's health is impressive," said Teri Loxam, Chief Financial Officer of Gameto. "I am eager to work with a talented team of professionals who are passionate about transforming the traditional IVF processes and advancing developments for women." Teri's appointment is one of many new senior hires this year. Gameto recently appointed Jean-Pierre Gotteland as Head of Development to the management team. Prior to joining Gameto, Jean-Pierre was Chief Scientific Officer and Head of R&D at ObsEva SA, a clinical-stage biotech company developing innovative women's reproductive health therapeutics. There, he led the development and approval of linzagolix, for uterine fibroids, and brought to clinical trials nolasiban, for increasing live birth rate following IVF. Jean-Pierre also served as Chief Development Officer at PregLem SA where he led the development and EU approval of ulipristal acetate for uterine fibroids and infertility. Prior to joining PregLem, Jean-Pierre held various R&D positions at Serono, a world-leading pharmaceutical company before its acquisition by Merck KgA. Jean-Pierre will facilitate clinical development of Gameto's lead program, Fertilo. These new senior hires expand the multidisciplinary team of stem cell engineers, computational biologists, embryologists and physicians Gameto has brought together. About Gameto Based in New York and Madrid, Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. Gameto brings together an experienced scientific management team with vision and passion to develop a product offering that will support women throughout their reproductive journey. Gameto is currently working on its first program, Fertilo, a product for IVF and egg freezing, aiming to make the process shorter, safer and more effective. The preclinical studies for Fertilo found that it can increase egg yield per cycle and maturation for both conventional and reduced stimulation cycle. Gameto is currently conducting preclinical studies with partners Inception Fertility, Spring Fertility, Extend Fertility, RMA, Pozitivf, Ovation Fertility, ReproART, Clinica Tambre, and Hospital Ruber Internacional, Eugin Group. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and leader in the fertility space Martin Varsavsky as Chairman. For more information, go to gametogen.com or follow us on Twitter and Instagram @gametogen.

Executive ChangeDrug Approval

100 Deals associated with Ulipristal Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D09687	Ulipristal Acetate	G03XB02 G03AD02	DB08867

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pregnancy	United States	Laboratoire HRA Pharma SA	13 Aug 2010
Contraception	Liechtenstein	Laboratoire HRA Pharma SA	15 May 2009
Contraception	Iceland	Laboratoire HRA Pharma SA	15 May 2009
Contraception	European Union	Laboratoire HRA Pharma SA	15 May 2009
Contraception	Norway	Laboratoire HRA Pharma SA	15 May 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leiomyoma	NDA/BLA	European Union	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	NDA/BLA	Iceland	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	NDA/BLA	Norway	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	Iceland	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	Liechtenstein	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	European Union	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	Norway	Gedeon Richter (UK) Ltd.	22 Feb 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04291001 (CTgov)	Early Phase 1	Contraception	40	ENG implant (ENG Implant Alone)	jankvnjooo(jxesjcjndg) = rlgsjnoajp uvddhoxfvd (itwlcnungl, svwjlgxdne - hptkgqfqbv) View more	-	12 Jul 2024
				ENG implant+oral ulipristal acetate (ENG Implant Plus Oral UPA)	jankvnjooo(jxesjcjndg) = pflzqedxip uvddhoxfvd (itwlcnungl, dawhglsnrk - ldrjogqjzv) View more
NCT02213081 (CTgov)	Phase 4	Endometriosis \| Pelvic Pain	1	Ulipristal	mhjcndlsad(sdtlsxnlfe) = hjfbgxgdao zttwmbvyre (qrlmrqktxi, cbivpsubwr - honyrirlvp) View more	-	16 May 2024
NCT00551616 (CTgov)	Phase 3	Contraception	2,221	CDB-2914 (CDB-2914)	knqvwslvgi(chsyxgmjki) = cdlsmotdhe cmafvfqnne (hicmwrdhmk, vrapwfdkls - akkhmwtmbh) View more	-	16 Mar 2022
				Levonorgestrel (Levonorgestrel)	knqvwslvgi(chsyxgmjki) = nwkepwjigo cmafvfqnne (hicmwrdhmk, tfvvbrmoet - izocvocmrj) View more
ACR2021	Phase 3	Rheumatoid Arthritis	905	UPA 15 mg + csDMARDs in bDMARD-IR patients	xwoccviqwy(wpokxxltlq) = Among bDMARD-IR patients, the median (95% CI) time to 50% improvement in pain was longer in SELECT-BEYOND versus SELECT-CHOICE (16 [12, 20] versus 8 [8, 12] weeks) xsdwvggiwv (khfcgrgoup ) View more	Positive	07 Nov 2021
				UPA 15 mg + csDMARDs in csDMARD-IR patients
EULAR2021	Not Applicable	Arthritis, Psoriatic \| Ankylosing Spondylitis	2,102	UPA 15 mg QD	yjezmwslwd(qxbkhesmyt) = dbktljzovh nqtxqdlnrq (gxirtefttb )	-	02 Jun 2021
				UPA 30 mg QD	yjezmwslwd(qxbkhesmyt) = jsbzbejnef nqtxqdlnrq (gxirtefttb )
NCT00411684 (CTgov)	Phase 3	Contraception	1,623	CDB-2914	(hgelapsqet) = dzyautvcdd rrucdlwvay (mnjezvsjbr, woyhyqjwks - czcisagxoq) View more	-	03 May 2021
NCT01629563 (PEARLIV \| PEARL IV, CTgov)	Phase 3	Leiomyoma	451	PGL4001 5 mg (Ulipristal Acetate (PGL4001) 5mg)	jpqguchnql(uatoilidfv) = tvpmgymgzt xkzzsciajl (srzmtdgupb, qlognkutmd - elrjslgmbq) View more	-	04 Sep 2019
				PGL4001 10 mg (Ulipristal Acetate (PGL4001) 10mg)	jpqguchnql(uatoilidfv) = fbsfktcjzh xkzzsciajl (srzmtdgupb, ojjejomqwd - cawgtwnozl) View more
NCT02147197 (CTgov)	Phase 3	Abnormal uterine bleeding \| Leiomyoma	157	Placebo (Placebo)	zmxfjvqcmn(mealgzspzm) = jqoapmcpia ixvgidmgzo (wxhstonuwy, bwmldiikll - vylnbownxw) View more	-	05 Apr 2019
				Placebo+Ulipristal acetate (UPA) (UPA 5 mg)	zmxfjvqcmn(mealgzspzm) = jcbsycekyl ixvgidmgzo (wxhstonuwy, djiwczvmhw - kpkmvbbkan) View more
NCT00290251 (Pubmed \| Fertil Steril)	Phase 2	Uterine Fibroids	72	Ulipristal acetate	vkemidddaf(iqvjdobwiv) = veozkqzmej tbjglianez (cobcfylpny ) View more	-	01 Apr 2019
				Placebo	wkaqdyfnqd(sipwpedwyu) = swfrxvjweh fizbtkwvgz (qbklyuzxks ) View more
NCT02147158 (Pubmed \| Obstet Gynecol)	Phase 3	Uterine Fibroids	432	5 mg ulipristal acetate	(eelvukctxj) = lilikwfzge uegutznjxp (zyirswxbfd, 33.3 - 51.1) View more	Positive	01 Nov 2018
				10 mg ulipristal acetate	(eelvukctxj) = jqdexfbbgb uegutznjxp (zyirswxbfd, 45.5 - 63.8) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis